What is peptide therapy, and how does it differ from conventional pharmacology?

Peptide therapy means the investigational use of short amino acid chains (peptides) to adjust biological processes. Most conventional drugs create new effects by blocking or activating specific targets. Peptides usually work differently. They raise or adjust the body's own signal pathways. This difference means peptide research aims to restore natural functions rather than replace them.

Which peptide categories have the strongest research support?

Tissue repair peptides (BPC-157, TB-500, GHK-Cu) have the largest preclinical record. Hundreds of studies exist. Growth hormone peptides (CJC-1295, Ipamorelin, Sermorelin) have some human trial data in specific cases. Cognitive peptides (Semax, Selank) have a smaller but growing record, mostly from Eastern European work. Metabolic and lifespan peptides (MOTS-c, Epitalon) are at earlier stages.

Are peptide therapies approved for clinical use?

Most research peptides on CompoundGuide lack approval from the FDA, EMA, or MHRA for any medical use. A few exceptions exist. Sermorelin was once FDA-approved as a diagnostic drug (Geref, now off the market). Tesamorelin is approved for HIV-related fat loss (Egrifta). Most compounds remain limited to research labs.

Can peptides from different categories be combined in research?

Cross-category links may exist in theory. For example, healing peptides with metabolic peptides might aid both tissue repair and energy use. Yet direct proof for such mixes is very thin. Most pair research stays in one category. Examples: CJC-1295 with Ipamorelin on the GH axis. BPC-157 with TB-500 in healing.

How do I evaluate the quality of peptide research?

Solid peptide research appears in peer-reviewed journals indexed in PubMed. Trust signals include: random assignment in human studies, clear methods, open funding data, and repeat results from separate groups. Preclinical work should name the test animal, dose plan, and measured results. Stay wary of claims based only on personal stories or unproven sources.

Research Guide

Peptide Therapy Benefits

Explore the scientific research behind peptide therapy benefits across tissue repair, cognitive function, metabolic health, longevity, and anti-aging. Evidence-based guide with PubMed citations.

Last updated May 16, 2026 6 min read

Type "do peptides work" into a search bar and you will get one blended answer — which is the first mistake.

"Peptides" is not one thing. A gut-repair compound, a growth hormone secretagogue, and a mitochondrial signal share about as much as a hammer, a thermostat, and a battery. All are tools. Each does a different job.

What connects them is method. Peptides are short chains of amino acids. They usually hold 3 to 50 links. They work by adjusting the body's own signaling networks. They do not force a single receptor. Research suggests this may have clear benefits for tissue repair, metabolic control, or cognitive function.

Their small size helps them cross biological barriers. They also avoid immune reaction risks that trouble larger protein drugs.

This guide maps five main research categories: tissue repair, growth hormone, cognitive support, metabolic health, and anti-aging. Each links to the compounds with the strongest evidence.

Treat this as a trailhead. Pick the category that fits your question. Then follow the page links for full detail.

Overview

Peptide research sorts by biological effect, not by brand name. Some compounds speed up tissue repair. Others raise growth hormone release. Others affect cognitive pathways, metabolic control, or immune function.

Lumping them together creates noise. Sorting them creates insight.

Five categories dominate current literature. Each has preclinical studies. Some even have early-phase human trials.

Each section below lists its lead compounds. It sketches what the evidence covers. It also links to full pages for deep detail.

Quick Comparison

Compound	Origin	Mechanism	Half-life	Admin Routes	Research Status
BPC-157	Synthetic pentadecapeptide (derived from gastric juice protein)	VEGF/EGF upregulation, mTOR pathway, nitric oxide system	~hours (preclinical estimate)	Subcutaneous, Intramuscular, Oral	Preclinical
TB-500	Synthetic fragment of Thymosin Beta-4 (aa 17-23)	Actin sequestration, VEGF angiogenesis, NF-κB suppression	~days (based on Tβ4 data)	Subcutaneous, Intramuscular	Preclinical
GHK-Cu	Naturally occurring copper tripeptide (Gly-His-Lys + Cu²⁺)	Copper-dependent collagen crosslinking, antioxidant gene expression	Minutes to hours in plasma	Subcutaneous, Topical	Preclinical + topical RCTs
CJC-1295	Synthetic GHRH analogue (with DAC for extended half-life)	GHRH receptor agonism → pulsatile GH secretion	6–8 days (with DAC); ~30 min (without DAC)	Subcutaneous, Intramuscular	Preclinical
Ipamorelin	Synthetic pentapeptide ghrelin mimetic	Selective GHSR-1a agonism → GH release (minimal cortisol/prolactin effect)	~2 hours	Subcutaneous, Intramuscular	Preclinical
Sermorelin	Synthetic GHRH(1-29) fragment	GHRH receptor activation → endogenous GH pulse amplification	~11–12 min (IV); longer subcutaneous	Subcutaneous, Intravenous	Clinical (FDA-approved diagnostic)
Tesamorelin	Synthetic GHRH analogue (modified for stability)	GHRH receptor agonism → IGF-1 elevation → visceral fat reduction	~26–38 min (IV); ~4–5 hours (SC estimated)	Subcutaneous	Clinical (FDA-approved for HIV lipodystrophy)
Semax	Synthetic ACTH(4-10) fragment with Pro-Gly-Pro modification	BDNF upregulation, enkephalinase inhibition, neurotrophic signaling	Short (minutes); nasal spray extends local bioavailability	Intranasal, Subcutaneous	Clinical (approved in Russia/CIS)
Selank	Synthetic tuftsin analogue with Pro-Gly-Pro modification	Enkephalinase inhibition, IL-6/TNF-α modulation, GABAergic interaction	Short (minutes); intranasal improves CNS access	Intranasal, Subcutaneous	Clinical (approved in Russia/CIS)
MOTS-c	Mitochondrial-derived peptide (encoded in mtDNA 12S rRNA region)	AMPK activation → insulin sensitivity, folate cycle regulation	Short in plasma (minutes); cellular effects persist	Subcutaneous, Intraperitoneal, Intravenous	Preclinical
AOD-9604	Modified hGH fragment (aa 177-191) with Tyr→Ala substitution	β3-adrenergic receptor pathway → lipolysis without IGF-1 elevation	~2–3 hours (limited PK data)	Subcutaneous, Oral	Preclinical
Epitalon	Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin	Telomerase activation, pineal melatonin regulation, p53 modulation	Short (minutes); biological effects persist beyond clearance	Subcutaneous, Intranasal	Preclinical
KPV	Synthetic tripeptide (Lys-Pro-Val) — α-MSH fragment	TNF-α/IL-6 suppression, intestinal epithelial barrier integrity	Short (minutes; limited PK data)	Subcutaneous, Oral, Topical	Preclinical

Compounds in This Guide

BPC-157

Gastrointestinal protection & systemic tissue repair

Full profile â†’

Tissue Repair and Regeneration

If peptide research has a flagship category, this is it. BPC-157 , TB-500 , and GHK-Cu have each been studied on skin, tendon, ligament, muscle, and gut lining. No other group on this page covers so many tissues.

Each one has a clear role. BPC-157 appears to raise VEGF and EGF levels. This drives blood vessel growth and cell division . TB-500 adjusts actin dynamics. Cells need this to move during wound closure . GHK-Cu adds copper for collagen cross-links. This boosts the strength of the final repair .

Read together, they suggest a shared idea. Support the body's own repair cascades. Do not override them. This is the opposite approach to hormone replacement.

A newer angle aims at inflammation itself. ** KPV ** is a short piece of alpha-melanocyte stimulating hormone (α-MSH). It has been studied for lowering TNF-α and IL-6. These two molecules drive chronic inflammation. KPV also helps seal the gut wall . This mix puts KPV at the crossroads of immune control and tissue repair. It may be most useful for gut-related contexts.

gut-healing tendon-repair wound-healing injury-recovery

CJC-1295

Growth hormone-releasing hormone analogue

Full profile â†’

Working the Growth Hormone Axis

The second group prompts the pituitary rather than replacing it. The pituitary is a small gland at the brain's base. It releases growth hormone (GH).

CJC-1295 , Ipamorelin , Sermorelin , and Tesamorelin each pull a different lever on the hypothalamic-pituitary-somatotropic axis. This axis is the hormone chain that raises natural GH release.

The short version: CJC-1295 is a modified GHRH analog. GHRH is a hormone that signals the pituitary to release GH. CJC-1295 produces long-lasting GH rise . Ipamorelin copies ghrelin through a separate pathway . Sermorelin copies natural GHRH but has a short half-life. Half-life is how long a drug stays active. Sermorelin's short life matches the body's natural pulses .

The open question: does keeping feedback loops intact lead to different long-term results than direct GH use? This spans body makeup, metabolic health, and maybe lifespan. All uses remain investigational.

muscle-growth fat-loss anti-aging

GHK-Cu

Skin regeneration & collagen synthesis

Full profile â†’

Anti-Aging and Skin Health

Some peptides fade as we age. One decline is well documented. Plasma levels of GHK-Cu drop by over 60% between young adulthood and age 60 . This drop tracks both visible and functional signs of aging.

Research suggests GHK-Cu may support collagen, elastin, and antioxidant gene activity . These effects made it dermatology's most-studied topical peptide. Research spans wound healing and skin quality.

** AOD-9604 ** appears here too. It has been studied for fat-metabolism effects. It does not carry the broader GH-axis effects of full-length hormone . Same trend, different tissue: keep the useful signal. Skip the body-wide side effects.

skin-health wound-healing anti-aging

MOTS-c

Mitochondrial-encoded peptide studied for metabolic regulation and longevity

Full profile â†’

Metabolic Health and Longevity

Mitochondria turned out to send signals too. Mitochondria are the cell's power plants.

** MOTS-c ** is a 16-link peptide built from mitochondrial DNA. It has been studied for effects on insulin sensitivity and glucose control . Under stress, it may move to the cell nucleus. There it helps adjust genes that govern energy balance.

** Epitalon ** is a short synthetic peptide. It copies epithalamin, a natural compound from the pineal gland. Epitalon has been explored for effects on telomerase and cell aging markers . Telomerase maintains the protective caps on chromosomes. Evidence remains early. Still, these compounds place peptides at the meeting point of metabolism and lifespan.

** AOD-9604 ** shows the category's surgical style. It is a modified piece of human growth hormone. Only part of the molecule remains (links 177 to 191). It has been studied for breaking down fat through the β3-adrenergic receptor . Unlike full hormone, it does not raise IGF-1 or blood sugar. The theme: keep the useful signal. Drop the rest.

metabolic-health anti-aging fat-loss

Semax

ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance

Full profile â†’

Cognitive and Neurological Support

Compounds that cross the blood-brain barrier open a different frontier: the mind itself. The blood-brain barrier is a wall that protects the brain from many substances.

Semax and Selank lead this group. Both come from fragments of adrenocorticotropic hormone (ACTH). ACTH is a hormone that signals the stress system. Both also come from Russian and Eastern European research.

Semax has been studied for raising brain-derived neurotrophic factor (BDNF). BDNF is a protein that helps brain cells grow. Semax has also been studied for cognition under stress . Selank has been studied for calm effects through the GABA system . GABA is a brain chemical that reduces nerve activity.

Their focus differs from the body-repair groups. They target the nervous system, not tissue. The evidence base is thinner than for repair peptides. Yet the biological grounding is solid. The closing section shows how these categories link more than they first appear.

cognitive-enhancement neuroprotection mood-support

How They Work Together

Linking Peptide Research Across Categories

The categories above look separate on a page. In a living body, they talk nonstop. Metabolic health shapes repair power. Brain health depends on blood vessel health. The GH-IGF-I axis touches both body makeup and skin quality.

This link poses one of the field's top open questions: could compounds from different categories interact body-wide — for better or worse? Most published studies test one compound alone. The systems-level question stays wide open. It is a true frontier, not a solved topic.

Existing combination studies stay in one lane. CJC-1295 plus Ipamorelin on the GH axis. BPC-157 plus TB-500 in healing. No one has mapped wider links with rigor.

Our research stacks follow this caution. The Healing Stack uses BPC-157 plus TB-500 . The Glow Blend uses BPC-157 plus GHK-Cu . The Growth Hormone Stack uses CJC-1295 plus Ipamorelin . Each pair works inside one category. Cross-category mixes remain theory — a frontier, not a finding. The next decade of studies will settle the issue.

Frequently Asked Questions

: Peptide therapy means the investigational use of short amino acid chains (peptides) to adjust biological processes. Most conventional drugs create new effects by blocking or activating specific targets. Peptides usually work differently. They raise or adjust the body's own signal pathways. This difference means peptide research aims to restore natural functions rather than replace them.
: Tissue repair peptides (BPC-157, TB-500, GHK-Cu) have the largest preclinical record. Hundreds of studies exist. Growth hormone peptides (CJC-1295, Ipamorelin, Sermorelin) have some human trial data in specific cases. Cognitive peptides (Semax, Selank) have a smaller but growing record, mostly from Eastern European work. Metabolic and lifespan peptides (MOTS-c, Epitalon) are at earlier stages.
: Most research peptides on CompoundGuide lack approval from the FDA, EMA, or MHRA for any medical use. A few exceptions exist. Sermorelin was once FDA-approved as a diagnostic drug (Geref, now off the market). Tesamorelin is approved for HIV-related fat loss (Egrifta). Most compounds remain limited to research labs.
: Cross-category links may exist in theory. For example, healing peptides with metabolic peptides might aid both tissue repair and energy use. Yet direct proof for such mixes is very thin. Most pair research stays in one category. Examples: CJC-1295 with Ipamorelin on the GH axis. BPC-157 with TB-500 in healing.
: Solid peptide research appears in peer-reviewed journals indexed in PubMed. Trust signals include: random assignment in human studies, clear methods, open funding data, and repeat results from separate groups. Preclinical work should name the test animal, dose plan, and measured results. Stay wary of claims based only on personal stories or unproven sources.

Summary

From wound cell mechanics to mitochondrial fuel-switching to the brain's roots of resilience, peptide research covers vast ground. It shares one method: pull specific signal chains from larger proteins. Then study them under controlled conditions.

Where the evidence stands is clear: peptides are biologically active compounds. Preclinical models show their mechanisms. Human trials have not yet shown whether those mechanisms lead to safe, effective, repeatable results.

The responsible path forward uses PubMed's primary studies. It needs clear awareness of drug rules. It rejects any jump from animal models to human claims without proof. This guide gives educational context. Real study design belongs to peer-reviewed evidence and institutional review. Now pick a category and explore.